Verve Therapeutics, Inc.
VERVNASDAQHealthcare
$11.13
+$0.03(+0.27%)
Market Cap$994044786
P/E Ratio—
52W High$11.405
52W Low$2.865
Verve Therapeutics, Inc. (VERV) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · VERV · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $32.33M | $11.76M | $1.94M | $0.00M | $0.00M |
| Cost of Revenue | $0.00M | $0.00M | $0.00M | $3.38M | $1.33M |
| Gross Profit | $32.33M | $11.76M | $1.94M | ($3.38M) | ($1.33M) |
| Gross Margin %(computed) | 100.00% | 100.00% | 100.00% | — | — |
| Operating Expenses | |||||
| R&D Expenses | $204.35M | $184.95M | $130.09M | $68.20M | $35.37M |
| G&A Expenses | $56.65M | $49.94M | $37.53M | $18.86M | $5.26M |
| Total Operating Expenses | $260.99M | $234.88M | $167.63M | $87.07M | $40.63M |
| Operating Income | ($228.66M) | ($223.12M) | ($165.69M) | ($87.07M) | ($40.63M) |
| Operating Margin %(computed) | -707.23% | — | — | — | — |
| Interest Income | $28.76M | $23.17M | $6.87M | $0.14M | $0.16M |
| Interest Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Income Before Tax | ($198.36M) | ($199.79M) | ($157.33M) | ($120.31M) | ($45.70M) |
| Income Tax Expense | $0.35M | $0.28M | $0.05M | $0.00M | $0.00M |
| Net Income | ($198.71M) | ($200.07M) | ($157.39M) | ($118.64M) | ($45.54M) |
| Net Margin %(computed) | -614.59% | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-2.36 | $-3.12 | $-2.91 | $-2.45 | $-0.94 |
| Wtd Avg Shares | 84.72M | 64.18M | 54.02M | 48.51M | 48.22M |
| EBITDA | ($221.91M) | ($217.67M) | ($162.88M) | ($85.53M) | ($39.30M) |
| EBITDA Margin %(computed) | -686.34% | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more Verve Therapeutics, Inc. data
About Verve Therapeutics, Inc. (VERV) Income Statement
Verve Therapeutics, Inc. (VERV) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2024, VERV reported revenue of $0.03B, gross profit of $0.03B (gross margin 100.00%), and net income of ($0.20B) — a net profit margin of -614.59%.
Frequently asked questions
VERV · 4 questionsVerve Therapeutics, Inc. (VERV) reported revenue of $0.03B for 2024, up 175.0% year-over-year.
VERV revenueVERV salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09